
Gilead Plans Affordable HIV Prevention Drug Access in Nigeria, 119 other Countries
Gilead Sciences announced its intention to make affordable versions of its innovative HIV prevention drug, lenacapavir, accessible in 120 low and middle-income countries. “This initiative will significantly reduce HIV infections,” the company, highlighting lenacapavir’s twice-yearly injection efficacy. In clinical trials in South Africa and Uganda, lenacapavir demonstrated remarkable success in preventing infections among women. A…